Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs 985

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Pipeline programs

Page 15 of 21

  1. Zilretta

    Pacira Ireland Limited

    Osteoarthritis of Hip

    phase 2 small molecule terminated

    1 trial

  2. Zr89

    Disc Medicine

    giant cell arteritis, rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  3. [68Ga]FAPI-46

    Disc Medicine

    giant cell arteritis - polymyalgia rheumatica spectrum disease

    phase 2 small molecule active

    1 trial

  4. amobarbital/Gel-One (one dose)

    United Therapeutics Europe Ltd

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  5. bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  6. corticosteroids

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Severe Colitis (ASC)

    phase 2 small molecule active

    1 trial

  7. cyclophosphamide

    Ultragenyx UK Limited

    Anemia, Hemolytic, Autoimmune

    phase 2 small molecule completed

    1 trial

  8. cytarabine

    Ultragenyx UK Limited

    Lupus Erythematosus, Systemic

    phase 2 small molecule completed

    1 trial

  9. edratide

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  10. etiprednol dicloacetate

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  11. glatiramer acetate

    Teva Pharma GmbH

    Crohns Disease

    phase 2 small molecule active

    1 trial

  12. honeybee venom (Apitoxin (Korea) Apitox (USA))

    Apimeds Pharmaceuticals US

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  13. infloran

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Enterocolitis, Necrotizing

    phase 2 other terminated

    1 trial

  14. mesenchymal stem cell

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 2 mab active

    1 trial

  15. nicotinamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cutaneous Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  16. pectin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  17. rituximab

    Chinese University of Hong Kong

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  18. sarilumab

    Sanofi-aventis Healthcare Pty Ltd

    Systemic Juvenile Idiopathic Arthritis (sJIA)

    phase 2 small molecule active

    1 trial

  19. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial

  20. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  21. vilamakitug

    XBiotech Germany GmbH

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  22. 1% icotinib hydrochloride cream

    Betta Pharmaceuticals Co.,

    Psoriasis

    phase 1 small molecule completed

    1 trial

  23. 1474-0002

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  24. 221458

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  25. 221615

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  26. 300134

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  27. 50 mg LX3305 QD

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  28. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Moderate to Severe Plaque Psoriasis

    phase 1 small molecule active

    1 trial

  29. 88545223PSO1001

    Janssen-Cilag International N.V.

    Psoriasis

    phase 1 other active

    1 trial

  30. A clinical study of MK-2420 in healthy men (MK-2420-003)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  31. A clinical study of MK-2420 in healthy people (MK-2420-002)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  32. A study to assess the effect of single and re... for Plaque Psoriasis

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 1 other active

    1 trial

  33. A148_01PK2408

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  34. AB-101

    Artiva Biotherapeutics

    Lupus Nephritis - WHO Class III

    phase 1 small molecule active

    1 trial

  35. AB-101

    Artiva Biotherapeutics

    Rheumatoid Arthritis

    phase 1 small molecule active

    1 trial

  36. ABI-M201

    ASSEMBLY BIOSCIENCES, INC.

    Ulcerative Colitis Chronic Mild

    phase 1 small molecule terminated

    1 trial

  37. AFN50 injection

    The First People's Hospital of Lianyungang

    Autoimmune Diseases

    phase 1 mab active

    1 trial

  38. AGMB129-01-CL-109

    Agomab Therapeutics NV

    Fibrostenotic Crohn’s disease

    phase 1 other active

    1 trial

  39. ALLO-329

    Allogene Therapeutics

    Systemic Lupus Erythematosus (With and Without Nephritis)

    phase 1 gene therapy active

    1 trial

  40. AN OPEN-LABEL for Intramuscular administration of…

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  41. APVO210

    Aptevo Therapeutics

    Psoriasis

    phase 1 mab terminated

    1 trial

  42. ARQ-151- cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial

  43. ARQ-154 Foam 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 1 small molecule completed

    1 trial

  44. ART-I02

    BRIGHT MINDS BIOSCIENCES INC.

    Arthritis, Rheumatoid

    phase 1 gene therapy active

    1 trial

  45. ATA3219

    Evidence Based Cataract Study Group

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial

  46. ATHENA CAR-T

    The First People's Hospital of Lianyungang

    Lupus Erythematosus, Systemic

    phase 1 mab active

    1 trial

  47. AUTO1-SL1

    Autolus GmbH

    Severe, Refractory Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  48. Allogeneic CD19/BCMA-targeted CAR-γδT cell injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory/Relapsed Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

985 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.